News

Tekes, the Finnish Funding Agency for Innovation, has granted a 2,903,000 EUR R&D loan to Herantis Pharma Plc. — a Finnish a pharmaceutical company that specializes in new drug research and development — to support its clinical study of Cerebral Dopamine Neurotrophic Factor (CDNF), a proprietary neuroprotective and…

The National Parkinson Foundation (NPF) has raised almost $1 million through the Moving Day, A Walk for Parkinson’s initiative that took place this spring. The funding will be invested in mission services in Washington, D.C., Tampa, and the Bay Areain CA, designed to improve the lives of patients…

Physician and scientist Mahlon DeLong, MD, was recognized for his achievements in the treatment of Parkinson’s disease with the 2015 Taubman Prize for Excellence in Translational Medical Science. The University of Michigan’s A. Alfred Taubman Medical Research Institute announced it was awarding DeLong for his contributions to improve the lives…

Researchers at Aarhus University and Aarhus University Hospital in Denmark recently reported new evidence that Parkinson’s disease development may actually start in the gut. The study entitled “Vagotomy and subsequent risk of Parkinson’s disease” was published in the journal Annals of Neurology.

In a recent study published in the journal JAMA Oncology, researchers from Taiwan found that Parkinson disease (PD) is associated with 16 different types of cancer. The study was conducted in an effort to understand the association on an East Asian population, since most investigations aiming to look…

A collaboration between the University College London Institute of Neurology, the University of Cambridge and the University of Sheffield found a new link between genetic mutations associated to Parkinson’s disease (PD). The study entitled “The Parkinson’s disease–linked proteins Fbxo7 and Parkin interact to mediate mitophagy” was published…

The U.S. Food and Drug Administration (FDA) on Friday, June 12 announced that it has approved an implantable deep brain stimulation device called the Brio Neurostimulation System, designed to help reduce symptoms associated with Parkinson’s disease and essential tremor, the latter a movement disorder and one of the most common…

Acorda Therapeutics, Inc. recently presented the results of its Phase 2b study of CVT-301, an inhaled levodopa (L-dopa) under development for patients with OFF episodes associated with Parkinson’s disease (PD). OFF episodes cause the re-emergence of PD motor symptoms, including muscle stiffness, impaired movement and tremor. Results from…

Researchers at the University of Pittsburgh School of Medicine and the VA Pittsburgh Healthcare System in Pennsylvania recently revealed that a gene therapy strategy targeting a key protein in Parkinson’s disease pathology – alpha-synuclein – can prevent disease development in a rat model. The study is entitled “…

Researchers at Trinity College Dublin, Ireland, discovered that specific cells in the brain called astrocytes develop an exaggerated reaction to inflammation in the context of neurodegenerative diseases. The study was recently published in The Journal of Neuroscience and is entitled “Astrocytes Are Primed by…